The past decade has been marked by the acceleration of our understanding of the molecular biology of cancer. Simultaneously, there have been increasing exigencies to diagnose, treat and follow cancer patients more economically. Biomarkers represent the marriage of science and economics. Biomarkers offer the potential to increase the precision of diagnosis, prognosis, and surveillance of urological malignancies. This issue presents the cutting-edge advances of biomarker technology to urologic oncology.
1. Cover image - p. Cover 2. Title page - p. Cover 3. Table of Contents - p. Cover 4. Copyright - p. Cover 5. CME Accreditation Page - p. Cover 6. Contributors - p. Cover 7. Forthcoming Issues - p. Cover 8. Foreword. Biomarkers in Urologic Cancer - p. Cover 9. Preface. Biomarkers in Urologic Cancer - p. Cover 10. The Prostate Health Index: Its Utility in Prostate Cancer Detection - p. Cover 11. New Genetic Markers for Prostate Cancer - p. Cover 12. Urinary Biomarkers for Prostate Cancer - p. Cover 13. 4-Kallikrein Test and Kallikrein Markers in Prostate Cancer Screening - p. Cover 14. Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer - p. Cover 15. Emerging Bladder Cancer Biomarkers and Targets of Therapy - p. Cover 16. Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer - p. Cover 17. Diagnostic Biomarkers in Eosinophilic Renal Neoplasms - p. Cover 18. Prognostic Biomarkers for Response to Vascular Endothelial Growth Factor–Targeted Therapy for Renal Cell Carcinoma - p. Cover 19. Prognostic Role of Cell Cycle and Proliferative Markers in Clear Cell Renal Cell Carcinoma - p. Cover 20. Current Clinical Applications of Testicular Cancer Biomarkers - p. Cover 21. MicroRNAs in Testicular Cancer Diagnosis and Prognosis - p. Cover 22. The Emerging Role and Promise of Biomarkers in Penile Cancer - p. Cover 23. Index - p. Cover
No hay muestra disponible
No hay ficha técnica disponible
The past decade has been marked by the acceleration of our understanding of the molecular biology of cancer. Simultaneously, there have been increasing exigencies to diagnose, treat and follow cancer patients more economically. Biomarkers represent the marriage of science and economics. Biomarkers offer the potential to increase the precision of diagnosis, prognosis, and surveillance of urological malignancies. This issue presents the cutting-edge advances of biomarker technology to urologic oncology.
1. Cover image - p. Cover 2. Title page - p. Cover 3. Table of Contents - p. Cover 4. Copyright - p. Cover 5. CME Accreditation Page - p. Cover 6. Contributors - p. Cover 7. Forthcoming Issues - p. Cover 8. Foreword. Biomarkers in Urologic Cancer - p. Cover 9. Preface. Biomarkers in Urologic Cancer - p. Cover 10. The Prostate Health Index: Its Utility in Prostate Cancer Detection - p. Cover 11. New Genetic Markers for Prostate Cancer - p. Cover 12. Urinary Biomarkers for Prostate Cancer - p. Cover 13. 4-Kallikrein Test and Kallikrein Markers in Prostate Cancer Screening - p. Cover 14. Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer - p. Cover 15. Emerging Bladder Cancer Biomarkers and Targets of Therapy - p. Cover 16. Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer - p. Cover 17. Diagnostic Biomarkers in Eosinophilic Renal Neoplasms - p. Cover 18. Prognostic Biomarkers for Response to Vascular Endothelial Growth Factor–Targeted Therapy for Renal Cell Carcinoma - p. Cover 19. Prognostic Role of Cell Cycle and Proliferative Markers in Clear Cell Renal Cell Carcinoma - p. Cover 20. Current Clinical Applications of Testicular Cancer Biomarkers - p. Cover 21. MicroRNAs in Testicular Cancer Diagnosis and Prognosis - p. Cover 22. The Emerging Role and Promise of Biomarkers in Penile Cancer - p. Cover 23. Index - p. Cover
No hay muestra disponible
No hay ficha técnica disponible
